Kim et al., 2023 - Google Patents
Randomized, two‐arm, noncomparative phase 2 study of olaparib plus cediranib or durvalumab in HRR‐mutated, platinum‐resistant ovarian cancer: A substudy of …Kim et al., 2023
- Document ID
- 1751575588770411245
- Author
- Kim Y
- Joung J
- Park E
- Kim J
- Lee J
- Lim J
- Kim S
- Choi C
- Kim H
- Chung J
- Kim B
- Lee J
- Publication year
- Publication venue
- International Journal of Cancer
External Links
Snippet
Choosing an optimal concomitant drug for combination with poly‐ADP ribose polymerase (PARP) inhibitor based on patient‐specific biomarker status may help increase to improve treatment efficacy in patients with ovarian cancer. However, the efficacy and safety of …
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gruber et al. | A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes | |
| O’Kane et al. | GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer | |
| Jiang et al. | Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial | |
| Pal et al. | Efficacy of BGJ398, a fibroblast growth factor receptor 1–3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations | |
| Bi et al. | Landscape of genomic alterations in pituitary adenomas | |
| Low et al. | Breast cancer: The translation of big genomic data to cancer precision medicine | |
| Lai et al. | BRCA-mutant pancreatic ductal adenocarcinoma | |
| Jovanović et al. | A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus in patients with stage II/III triple-negative breast cancer (TNBC): responses and long-term outcome correlated with increased frequency of DNA damage response gene mutations, TNBC subtype, AR status, and Ki67 | |
| Butowski et al. | Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study | |
| Lok et al. | PARP inhibitor activity correlates with SLFN11 expression and demonstrates synergy with temozolomide in small cell lung cancer | |
| Ho et al. | A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma | |
| Horbinski et al. | Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas | |
| Stadlmann et al. | Epithelial growth factor receptor status in primary and recurrent ovarian cancer | |
| Hirst et al. | Licofelone enhances the efficacy of paclitaxel in ovarian cancer by reversing drug resistance and tumor stem-like properties | |
| Nazha et al. | Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune‐checkpoint inhibitor‐related biomarkers | |
| Kim et al. | Randomized, two‐arm, noncomparative phase 2 study of olaparib plus cediranib or durvalumab in HRR‐mutated, platinum‐resistant ovarian cancer: A substudy of KGOG 3045 | |
| Hibi et al. | FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib | |
| Shi et al. | Cisplatin combined with irinotecan or etoposide for untreated extensive‐stage small cell lung cancer: a multicenter randomized controlled clinical trial | |
| Shah et al. | Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers | |
| Lambrechts et al. | Genetic markers of bevacizumab-induced hypertension | |
| Wang et al. | A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer | |
| Petrelli et al. | BRCA2 germline mutations identify gastric cancers responsive to PARP inhibitors | |
| Gbenedio et al. | RasGRP1 is a potential biomarker for stratifying anti-EGFR therapy response in colorectal cancer | |
| Takahashi et al. | Predictive value of EGFR mutation in non–small‐cell lung cancer patients treated with platinum doublet postoperative chemotherapy | |
| Gomez-Miragaya et al. | Chromosome 12p amplification in triple-negative/BRCA1-mutated breast cancer associates with emergence of docetaxel resistance and carboplatin sensitivity |